Patent Exclusivity Losses Push AstraZeneca's Q4 Profit Down 28%
AstraZeneca's profit declines 28% as gains in new treatments are more than offset by key patent losses in the U.S. and unfavorable foreign currency translation.
Eli Lilly & Co.: Cymbalta Sales Slide Begins
Eli Lilly's top selling drug has lost patent protection, making this an important transition year for the company.
3 Stocks to Get on Your Watchlist
An exciting oncology-focused biopharma ready to deliver results, a possible bargain-basement price on a deep-sea driller, and a potentially overvalued social-gaming company are today's must-watch stocks.